Factors associated with 1,25-dihydroxyvitamin D3 concentrations in liver transplant recipients: a prospective observational longitudinal study
详细信息 查看全文
- 作者：Agnieszka Prytuła ; Johan Vande Walle ; Hans Van Vlierberghe ; Jean-Marc Kaufman…
- 关键词：25 ; Hydroxyvitamin D3 ; 1 ; 25 ; Dihydroxyvitamin D3 ; Tacrolimus ; Liver transplantation
- 刊名：Endocrine
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：52
- 期：1
- 页码：93-102
- 全文大小：549 KB
- 参考文献：1.C.G. Krol, O.M. Dekkers, H.M. Kroon, T.J. Rabelink, B. van Hoek, N.A. Hamdy, Longitudinal changes in BMD and fracture risk in orthotopic liver transplant recipients not using bone-modifying treatment. J. Bone Miner. Res. 29(8), 1763–1769 (2014). doi:10.1002/jbmr.2214 CrossRef PubMed
2.S. Giannini, M. Nobile, M. Ciuffreda, R.M. Iemmolo, L. Dalle Carbonare, N. Minicuci, F. Casagrande, C. Destro, G.E. Gerunda, L. Sartori, G. Crepaldi, Long-term persistence of low bone density in orthotopic liver transplantation. Osteoporos. Int. 11(5), 417–424 (2000). doi:10.1007/s001980070109 CrossRef PubMed
3.A. Monegal, M. Navasa, N. Guanabens, P. Peris, F. Pons, M.J. Martinez de Osaba, J. Ordi, A. Rimola, J. Rodes, J. Munoz-Gomez, Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos. Int. 12(6), 484–492 (2001). doi:10.1007/s001980170094 CrossRef PubMed
4.P.P. Reese, R.D. Bloom, H.I. Feldman, A. Huverserian, A. Thomasson, J. Shults, T. Hamano, S. Goral, A. Shaked, K. Olthoff, M.R. Rickels, M. Bleicher, M.B. Leonard, Changes in vitamin D binding protein and vitamin D concentrations associated with liver transplantation. Liver Int. 32(2), 287–296 (2012). doi:10.1111/j.1478-3231.2011.02638.x CrossRef PubMed PubMedCentral
5.K.A. Simo, S. Sereika, N. Bitner, K.N. Newton, D.A. Gerber, Medical epidemiology of patients surviving ten years after liver transplantation. Clin. Transplant. 25(3), 360–367 (2011). doi:10.1111/j.1399-0012.2010.01305.x CrossRef PubMed
6.C. Francoz, F. Durand, A new look at renal dysfunction in the cirrhotic patient. Crit. Care 16(2), 118 (2012). doi:10.1186/cc11207 PubMed PubMedCentral
7.D.E. Prosser, G. Jones, Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 29(12), 664–673 (2004). doi:10.1016/j.tibs.2004.10.005 CrossRef PubMed
8.Z. Wang, E.G. Schuetz, Y. Xu, K.E. Thummel, Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J. Steroid Biochem. Mol. Biol. 136, 54–58 (2013). doi:10.1016/j.jsbmb.2012.09.012 CrossRef PubMed PubMedCentral
9.Y. Xu, T. Hashizume, M.C. Shuhart, C.L. Davis, W.L. Nelson, T. Sakaki, T.F. Kalhorn, P.B. Watkins, E.G. Schuetz, K.E. Thummel, Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol. Pharmacol. 69(1), 56–65 (2006). doi:10.1124/mol.105.017392 PubMed
10.C.M. Spencer, K.L. Goa, J.C. Gillis, Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54(6), 925–975 (1997)CrossRef PubMed
11.U. Christians, W. Jacobsen, L.Z. Benet, A. Lampen, Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 41(11), 813–851 (2002). doi:10.2165/00003088-200241110-00003 CrossRef PubMed
12.K. Izuishi, H. Wakabayashi, T. Ohnishi, H. Maeta, T. Maeba, Y. Ichikawa, Effects of an immunosuppressive agent, tacrolimus (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems in rat liver microsomes. Int. J. Biochem. Cell Biol. 29(6), 921–928 (1997)CrossRef PubMed
13.E. Stein, P. Ebeling, E. Shane, Post-transplantation osteoporosis. Endocrinol. Metab. Clin. N. Am. 36(4), 937–963; viii (2007). doi:10.1016/j.ecl.2007.07.008
14.B. Stein, B.P. Halloran, T. Reinhardt, G.W. Engstrom, C.W. Bales, M.K. Drezner, K.L. Currie, M. Takizawa, J.S. Adams, S. Epstein, Cyclosporin-A increases synthesis of 1,25-dihydroxyvitamin D3 in the rat and mouse. Endocrinology 128(3), 1369–1373 (1991). doi:10.1210/endo-128-3-1369 CrossRef PubMed
15.C.T. Lee, H.Y. Ng, Y.H. Lien, L.W. Lai, M.S. Wu, C.R. Lin, H.C. Chen, Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am. J. Nephrol. 34(1), 87–94 (2011). doi:10.1159/000328874 CrossRef PubMed
16.P. Evenepoel, M. Naesens, K. Claes, D. Kuypers, Y. Vanrenterghem, Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am. J. Transplant. 7(5), 1193–1200 (2007). doi:10.1111/j.1600-6143.2007.01753.x CrossRef PubMed
17.B. Casetta, I. Jans, J. Billen, D. Vanderschueren, R. Bouillon, Development of a method for the quantification of 1alpha,25(OH)2-vitamin D3 in serum by liquid chromatography tandem mass spectrometry without derivatization. Eur. J. Mass Spectrom. 16(1), 81–89 (2010). doi:10.1255/ejms.1024 CrossRef
18.A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocr. Metab. 96(1), 53–58 (2011). doi:10.1210/Jc.2010-2704 CrossRef PubMed PubMedCentral
19.R.B. Payne, A.J. Little, R.B. Williams, J.R. Milner, Interpretation of serum calcium in patients with abnormal serum proteins. Br. Med. J. 4(5893), 643–646 (1973)CrossRef PubMed PubMedCentral
20.A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro 3rd, H.I. Feldman, J.W. Kusek, P. Eggers, F. Van Lente, T. Greene, J. Coresh, E.P.I. Ckd, A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604–612 (2009)CrossRef PubMed PubMedCentral
21.P.S. Kamath, W.R. Kim, Advanced Liver Disease Study Group, The model for end-stage liver disease (MELD). Hepatology 45(3), 797–805 (2007). doi:10.1002/hep.21563 CrossRef PubMed
22.M.F. Holick, Vitamin D deficiency. N. Engl. J. Med. 357(3), 266–281 (2007). doi:10.1056/NEJMra070553 CrossRef PubMed
23.P. White, N. Cooke, The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol. Metab. 11(8), 320–327 (2000)CrossRef PubMed
24.M. Speeckaert, G. Huang, J.R. Delanghe, Y.E. Taes, Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin. Chim. Acta 372(1–2), 33–42 (2006). doi:10.1016/j.cca.2006.03.011 CrossRef PubMed
25.N.E. Cooke, J.G. Haddad, Vitamin D binding protein (Gc-globulin). Endocr. Rev. 10(3), 294–307 (1989). doi:10.1210/edrv-10-3-294 CrossRef PubMed
26.C. Francoz, D. Prie, W. Abdelrazek, R. Moreau, A. Mandot, J. Belghiti, D. Valla, F. Durand, Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl. 10, 1169–1177 (2010). doi:10.1002/lt.22128 CrossRef
27.A. Moulas, A. Challa, N. Chaliasos, P.D. Lapatsanis, Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in beta-thalassaemia. Acta Paediatr. 86(6), 594–599 (1997)CrossRef PubMed
28.M. Petkovich, G. Jones, CYP24A1 and kidney disease. Curr. Opin. Nephrol. Hypertens. 20(4), 337–344 (2011). doi:10.1097/MNH.0b013e3283477a7b CrossRef PubMed
29.A.H. Berg, C.E. Powe, M.K. Evans, J. Wenger, G. Ortiz, A.B. Zonderman, P. Suntharalingam, K. Lucchesi, N.R. Powe, S.A. Karumanchi, R.I. Thadhani, 24,25-Dihydroxyvitamin D3 and vitamin D status of community-dwelling black and white Americans. Clin. Chem. 61(6), 877–884 (2015). doi:10.1373/clinchem.2015.240051 CrossRef PubMed PubMedCentral
30.V. Lamba, J.C. Panetta, S. Strom, E.G. Schuetz, Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J. Pharm. Exp. Ther. 332(3), 1088–1099 (2010). doi:10.1124/jpet.109.160804 CrossRef
31.K.E. Thummel, C. Brimer, K. Yasuda, J. Thottassery, T. Senn, Y. Lin, H. Ishizuka, E. Kharasch, J. Schuetz, E. Schuetz, Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol. Pharmacol. 60(6), 1399–1406 (2001)PubMed
32.T. Nijenhuis, J.G. Hoenderop, R.J. Bindels, Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J. Am. Soc. Nephrol. 15(3), 549–557 (2004)CrossRef PubMed
33.D. Vanderschueren, S.R. Pye, T.W. Oneill, D.M. Lee, I. Jans, J. Billen, E. Gielen, M. Laurent, F. Claessens, J.E. Adams, K.A. Ward, G. Bartfai, F.F. Casanueva, J.D. Finn, G. Forti, A. Giwercman, T.S. Han, I.T. Huhtaniemi, K. Kula, M.E. Lean, N. Pendleton, M. Punab, F.C. Wu, S. Boonen, Active vitamin D (1,25-dihydroxyvitamin D) and bone health in middle-aged and elderly men: the European Male Aging Study (EMAS). J. Clin. Endocrinol. Metab. 98(3), 995–1005 (2013). doi:10.1210/jc.2012-2772 CrossRef PubMed
34.A. Levin, G.L. Bakris, M. Molitch, M. Smulders, J. Tian, L.A. Williams, D.L. Andress, Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71(1), 31–38 (2007). doi:10.1038/sj.ki.5002009 CrossRef PubMed
35.R. Shroff, M. Egerton, M. Bridel, V. Shah, A.E. Donald, T.J. Cole, M.P. Hiorns, J.E. Deanfield, L. Rees, A bimodal association of vitamin D levels and vascular disease in children on dialysis. J. Am. Soc. Nephrol. 19(6), 1239–1246 (2008). doi:10.1681/ASN.2007090993 CrossRef PubMed PubMedCentral
36.R.L. Corey, M.D. Whitaker, M.D. Crowell, M.T. Keddis, B. Aqel, V. Balan, T. Byrne, E. Carey, D.D. Douglas, M.E. Harrison, H.E. Vargas, J. Rakela, Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end-stage liver disease and normal serum creatinine awaiting liver transplantation. Clin. Transplant. 28(5), 579–584 (2014). doi:10.1111/ctr.12351 CrossRef PubMed
37.I.H. de Boer, B. Kestenbaum, A.B. Shoben, E.D. Michos, M.J. Sarnak, D.S. Siscovick, 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J. Am. Soc. Nephrol. 20(8), 1805–1812 (2009). doi:10.1681/ASN.2008111157 CrossRef PubMed PubMedCentral
38.O. Jirapongsananuruk, I. Melamed, D.Y. Leung, Additive immunosuppressive effects of 1,25-dihydroxyvitamin D3 and corticosteroids on TH1, but not TH2, responses. J. Allergy Clin. Immunol. 106(5), 981–985 (2000). doi:10.1067/mai.2000.110101 CrossRef PubMed
39.C.A. Redaelli, M. Wagner, D. Gunter-Duwe, Y.H. Tian, P.F. Stahel, L. Mazzucchelli, R.A. Schmid, M.K. Schilling, 1alpha,25-dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int. 61(1), 288–296 (2002). doi:10.1046/j.1523-1755.2002.00101.x CrossRef PubMed
40.L. Cianferotti, C. Cricelli, J.A. Kanis, R. Nuti, J.Y. Reginster, J.D. Ringe, R. Rizzoli, M.L. Brandi, The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine (2015). doi:10.1007/s12020-015-0606-x
41.E. Hustert, M. Haberl, O. Burk, R. Wolbold, Y.Q. He, K. Klein, A.C. Nuessler, P. Neuhaus, J. Klattig, R. Eiselt, I. Koch, A. Zibat, J. Brockmoller, J.R. Halpert, U.M. Zanger, L. Wojnowski, The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9), 773–779 (2001)CrossRef PubMed
42.P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P.B. Watkins, A. Daly, S.A. Wrighton, S.D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, M.S. Boguski, E. Schuetz, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383–391 (2001). doi:10.1038/86882 CrossRef PubMed - 作者单位：Agnieszka Prytuła (1)
Johan Vande Walle (1)
Hans Van Vlierberghe (2)
Jean-Marc Kaufman (3)
Tom Fiers (4)
Jo Dehoorne (1)
Ann Raes (1)
1. Pediatric Nephrology and Rheumatology Department, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium
2. Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
3. Department of Endocrinology, Ghent University Hospital, Ghent, Belgium
4. Department of Clinical Chemistry, Ghent University Hospital, Ghent, Belgium - 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
- 出版者：Springer US
- ISSN：1559-0100
文摘
The aim of the study was to identify factors associated with 1,25(OH)2D3 concentrations in liver transplant recipients with emphasis on the renal function and catabolism. We also tested the hypothesis that tacrolimus increases 1,25(OH)2D3 concentrations. Serum 25(OH)D3, 1,25(OH)2D3, and 24,25(OH)2D3 were measured in 41 patients before, at 2 weeks and 3 months after transplantation. Dose-adjusted tacrolimus concentration was used as a surrogate marker of CYP3A4 activity. Factors associated with 1,25(OH)2D3 were identified using multivariate linear regression analysis. The median 1,25(OH)2D3 levels remained stable: 55 versus 46 pg/ml (P = 0.36) despite an increase in 25(OH)D3 from 18 ng/ml at baseline to 26 ng/ml (P = 0.03), serum albumin (34 to 41 g/l, P = 0.02), and comparable eGFR at baseline and month 3 (94 and 92 ml/min, respectively, P = 0.15). At 3 months 19 % of patients had 1,25(OH)2D3 < 25 pg/ml. Low eGFR and a low dose-adjusted tacrolimus concentration were both independently associated with 1,25(OH)2D3 at 3 months. Liver transplant recipients with impaired renal function or a low dose-adjusted tacrolimus concentration suggesting a high CYP3A4 are at risk of low 1,25(OH)2D3 concentrations. The use of tacrolimus does not lead to an increase in 1,25(OH)2D3 concentrations in a clinical setting.